Results 241 to 250 of about 798,481 (288)

MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors. [PDF]

iScience
Kim H, Lebeau B, Papadopoli D, Jovanovic P, Russo M, Avizonis D, Morita M, Afzali F, Ursini-Siegel J, Postovit LM, Witcher M, Topisirovic I.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

mTOR inhibitors and diabetes

Diabetes Research and Clinical Practice, 2015
The mammalian target of rapamycin (mTOR) inhibitors are drugs, primarily used as immunosuppressors that are now frequently used as antineoplastic therapies in various cancers (such as advanced renal cell carcinoma, advanced breast cancer, progressive pancreatic neuroendocrine tumors).
Bruno Vergès, Bertrand Cariou
exaly   +3 more sources

mTOR inhibitors in cancer therapy

F1000Research, 2016
The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers.
Jianling Xie, Christopher G. Proud, Xuemin Wang   +2 more
exaly   +3 more sources

Mechanisms of resistance to mTOR inhibitors

Critical Reviews in Oncology/Hematology, 2020
In several tumors the PI3K/AKT/mTOR pathway is frequently disrupted, an event that results in uncontrolled cell proliferation and tumor growth. Through the years, several compounds have been developed to inhibit the pathway at different steps: the mammalian target of rapamycin (mTOR) seemed to be the most qualified target. However, this kinase has such
Luigi Formisano, Fabiana Napolitano, Roberto Bianco   +2 more
exaly   +4 more sources

mTOR inhibitors in cancer therapy

Cancer Letters, 2012
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors.
Mark Evers, Yekaterina Y Zaytseva, Pat Gulhati   +2 more
exaly   +3 more sources

Research progress of mTOR inhibitors

European Journal of Medicinal Chemistry, 2020
Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr) protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein family. mTOR exists as two types of protein complex: mTORC1 and mTORC2, which act as central controller regulating processes of cell metabolism, growth, proliferation ...
Yifan Chen
exaly   +3 more sources

Pharmacodynamic Monitoring of mTOR Inhibitors

Therapeutic Drug Monitoring, 2019
Abstract: Pharmacodynamic (PD) monitoring may complement routine pharmacokinetic monitoring of mTOR inhibitors (mTORis) in an attempt to better guide individualized sirolimus (SRL) or everolimus (EVR) treatment after organ transplantation. This review focuses on current knowledge about PD biomarkers for personalized mTORi therapies. Different
Olga, Millán, Eberhard, Wieland, Pierre, Marquet, Mercè, Brunet   +3 more
openaire   +2 more sources